New clinical trial shows Yuwell Anytime CT3 CGM delivers high accuracy with MARD of 6.9% in early stages of type 2 diabetes

Urathon Europe Ltd today announced the publication of a new study in the British Journal of Nursing, demonstrating that the Anytime CT3 Continuous Glucose Monitoring (CGM) system delivers high‑level accuracy, with a Mean Absolute Relative Difference (MARD) of 6.9% in early stages of type 2 diabetes. These findings validate the accuracy demonstrated in the Anytime CT3 CGM registration study and show that Anytime CT3 matches the performance of today’s leading, clinically trusted CGM systems used in routine diabetes care.

The study was conducted independently by researchers at the University of Leeds, ensuring that the evaluation of Anytime CT3’s performance was carried out without involvement in the study design, data collection or analysis by Yuwell or Urathon. The trial was conducted by Dr’s Lancaster, Edwards, Harper, Garner and Utley, who bring extensive experience in diabetes and clinical research to the work.

The trial evaluated the performance of the Anytime CT3 against capillary blood glucose measurements in adults living with type 2 diabetes. Accuracy was assessed across a wide spectrum of glucose values and under real‑world conditions, with MARD as the primary endpoint. A MARD of 6.9% in people with type 2 diabetes shows that Anytime CT3 readings on average differed by less than 7% from values measured with a commonly used blood glucose meter. This level of accuracy supports its use in guiding everyday treatment decisions and lifestyle choices.

The study found that above 99% of paired readings fell within clinically safe error zones, and that accuracy was maintained across all analysed glucose levels and throughout the full sensor wear period. Taken together, these findings show that Anytime CT3 provides reliable, consistent glucose data suitable for use in prediabetes and type 2 diabetes, including for individuals who may be new to CGM.

“We are absolutely delighted with these results,” said Hugh Sims-Hilditch, Chairman at Urathon. “A MARD of 6.9% (in early stage type 2 diabetes) confirms that Anytime CT3 offers the level of accuracy clinicians and people with diabetes expect from a leading CGM system, while also opening up a more accessible and affordable option for people living with prediabetes and type 2 diabetes. This is a major milestone for the Anytime CT3 platform and for our mission to broaden access to high‑quality glucose data.”

By providing real‑time glucose readings, trends and alerts, the Anytime CT3 helps users understand how food, activity, medications and stress affect their glucose levels, turning data into actionable insight. The new clinical trial adds to growing evidence that accurate CGM can support better glycaemic outcomes and quality of life, particularly when combined with structured education and ongoing clinical support.

The full article, ‘Accuracy and performance of the Yuwell Anytime CT3 continuous glucose monitoring device’  is now available online from the British Journal of Nursing:https://www.magonlinelibrary.com/doi/abs/10.12968/bjon.2026.0009